Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Paroxysmal Nocturnal Hemoglobinuria (PNH)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

    Contact: Study coordinator (Serban Morojanu) · moroiasa@cinj.rutgers.edu · +1 732-235-7577
    Contact: Principal Investigator (Richard DRACHTMAN)
  • Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Ariel Rivera) · riveraa12@chop.edu · +1 267 425 2136
    Contact: Principal Investigator (Timothy Olson)
  • St Jude Childrens Research Hospital, Memphis, Tennessee, United States

    Contact: Study coordinator (Kelsey Ray) · kelsey.ray@stjude.org
    Contact: Principal Investigator (Marcin Wlodarski)
  • Novartis Investigative Site, Brasília, Federal District, Brazil

  • Novartis Investigative Site, Natal, Rio Grande do Norte, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Santo André, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Utrecht, Netherlands

מובילי המחקר
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals